فهرست مطالب

  • Volume:12 Issue: 1, 2019
  • تاریخ انتشار: 1397/12/01
  • تعداد عناوین: 7
|
  • Ali Dianatpour , Sepideh Faramarzi , Soudeh Ghafouri, Fard * Page 1
    Context: Several studies have assessed the associations between BRCA1-interacting protein 1 (BRIP1) polymorphisms and risk of breast cancer. However, their results were mostly inconsistent and questionable.
    Objectives
    The aim of the current study was to appraise the association between BRIP1 variants and susceptibility to breast cancer through performing a meta-analysis.
    Data Sources: We investigated and gathered English literature existed in Medline, PubMed, Embase, Web of Science, and Google Scholar (up to January 2018) by the search terms “BRIP1 gene”, “breast cancer”, “SNPs”, and “polymorphism”.
    Results
    Case-control researches with almost identical strategies and adequate information for calculation of odds ratio (OR) with 95% confidence interval (CI) were included in the present study. Consequently, 3 publications in distinct ethnic groups including 986 cases and 1087 controls were chosen. The meta-analysis showed that the single-nucleotide polymorphism of rs4988344 in the BRIP1 gene was associated with breast cancer risk in homozygous (P = 0.46 for heterogeneity, OR = 1.66, 95% CI = [1.05, 2.63]) and recessive models (P = 0.44, OR = 1.62, 95% CI = [1.07, 2.46]), while rs7213430 was associated with breast cancer in dominant model (P = 0.03 for heterogeneity, OR = 0.74, 95% CI = [0.55, 0.98]).
    Conclusions
    The current meta-analysis showed the association between certain BRIP1 polymorphisms and breast cancer risk.
    Keywords: BRIP1, Breast Cancer, Meta-Analysis
  • Zinatossadat Bouzari , Hadiseh Rahimi , Hemmat Gholinia , Karimollah Hajian, Tilaki , Mohammad Jafar Soleimani , Shahla Yazdani * Page 2
    Background
    Distinguishing between malignant and benign ovarian masses is necessary to refer patients to centers with experience in the surgical.
    Objectives
    The aim of this study was to analyze the diagnostic value of the tumor markers, including risk of malignancy index (RMI), human epididymis protein 4 (HE4), cancer antigen125 (CA125), and risk of ovarian malignancy algorithm (ROMA) in ovarian mass.
    Methods
    One hundred patients with ovarian masses were assessed for the tumor markers ROMA, HE4, RMI, and CA125. The sensitivity and specificity of each parameter were calculated, using receiver-operating characteristic curves (ROCs) according to the area under the curve (AUC) for each method.
    Results
    The median CA125, HE4, RMI, and ROMA serum levels had significant difference between malignant and benign masses in the overall assessment (P < 0.001). The AUCs were 0.83 (CA125), 0.88 (HE4), 0.85 (RMI), and 0.92 (ROMA) for benign vs. malignant masses in all the patients. The comparison of ROC curves was carried out, using a pairwise comparison method, and no differences were found among 4 methods.
    Conclusions
    The results based on the AUC markers of CA125, HE4, RMI, and ROMA revealed that the accuracy trend of ROMA was higher than that of CA125, HE4, and RMI in all the patients and each group of pre- and post-menopausal patients.
    Keywords: CA125, HE4, RMI, ROMA, Ovarian Cancer, Tumor Markers
  • Mohammad Esmaeil, Akbari , Nahid Nafissi , Seied Rabi Mahdavi , Hamid Reza Mirzaei , Azam Salati , Maryam Khayamzade , Zeinab Shormeij , Jafar Shakeri , Mojgan Nabatzadeh , Minoo Shahani , Marzieh Kiaee , Sajad Noorian Noorian , Hassan Moayeri * Page 3
    Background
    Breast conserving surgery (BCS) and its following radiotherapy is an accepted therapeutic method for patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC).
    Objectives
    The aim of this study was to investigate the effect of intraoperative electron radiotherapy on women with breast cancer (invasive lobular and ductal carcinoma).
    Methods
    Between August 2013 and September 2017, 968 patients, who were referred to Cancer Research Center, Shahid Beheshti University of Medical Sciences with invasive breast cancer, were treated with breast-conserving surgery and radiotherapy. Of those, 426 patients received a tumor bed boost with intraoperative electron radiotherapy (IOERT) during lumpectomy (58 patients with pure invasive lobular carcinoma, 239 patients with pure invasive ductal carcinoma, and 129 patients with other diagnoses). 542 patients received a tumor bed boost with conventional external beam radiotherapy post lumpectomy (24 patients with pure invasive lobular carcinoma, 418 patients with pure invasive ductal carcinoma, and 100 patients with other diagnoses). The patients were followed up to 49 months. A comprehensive list of clinical and pathologic features was evaluated for all patients. We retrospectively analyzed outcomes of breast cancer treated with boost intraoperative electron radiotherapy (pure ILC and IDC groups) and in other group treated with boost conventional external beam radiotherapy (pure ILC group).
    Results
    None of the ILC patients had recurrence in the two groups. The four-year survival rate for ILC patients was 100%, but in the IDC group the survival rate was 97%. Survival analyses showed patients with IDC had a higher risk of ipsilateral breast tumor recurrence (IBTR) and metastasis.
    Conclusions
    Overall, the rates of IBTR and metastasis in the ILC boost IOERT group were significantly low. This finding suggests that IOERT technique deployment in ILC had no inferiority compared with the control group.
    Keywords: IOERT, Ipsilateral Breast Recurrence, ILC, IDC
  • Seyedeh Afrooz Azimi , Hamid Reza Sadegh Nia , Alireza Mosavi Jarrahi , Hamid Reza Jamaati , Mehdi Kazempour Dizaji , Hossein Dargahi , Naghmeh Bahrami , , Alireza Pasdar , , Adnan Khosravi , Naeim Bahrami , Shadi Daghighi , Abdolreza Mohamadnia * Page 4
    Background
    Lung cancer is the leading cause of death, related to cancer in both men and women. MicroRNAs (miRNAs) play key roles in regulating the genes that are responsible for apoptosis, and regulation of gene expression. MicroRNA expression is deregulated in cancer. Many efforts have been made to detect cancer biomarkers. Extracellular miRNAs, which are directly released from tumors, can be detected in circulating blood.
    Objectives
    The aim of this study was to examine the expression of miRNA-205 and -21 in lung cancer patients relative to healthy controls.
    Methods
    This cross sectional study was performed in 50 healthy blood sample controls and 50 non-small cell lung cancer (NSCLC) blood samples. The expression of two miRNAs (miR-21 and miR-205) in peripheral blood mononuclear cells (PBMCs) was evaluated, using real-time polymerase chain reaction (real-time PCR) techniques. Statistical tests were carried out via the Mann-Whitney test.
    Results
    The miR-205 levels of expression in the patients with lung cancer significantly increased in comparison to healthy controls (6.8 ± 0.42 and 1.2 ± 0.19, respectively), (P = 0.014). The expression of miR-21 in lung cancer (5.2 ± 0.52) significantly increased compared to the control group (1.6 ± 0.14) (P < 0.001).
    Conclusions
    Based on our findings, lung cancer can enhance the ectopic expression of several miRNAs, which, in turn, play key roles in impaired apoptosis and further cancerous progression.
    Keywords: Expression, miR-21, miR-205, Non-Small Cell Lung Cancer
  • Mansour Rezazadeh Azari , Mohammad Esmail Akbari , Mohammad Bagher Abdollahi , Hamid Reza Mirzaei , Ali Salehi Sahlabadi , Ramin Tabibi , Alireza Rahmati , Davoud Panahi * Page 5
    Background
    Antineoplastic drugs as chemotherapy agents are used for various therapeutic purposes. Occupational exposure to antineoplastic drugs is possible through inhalation, skin contact, skin absorption, and digestive or injection. Assessment of occupational exposure of staff working with anti-neoplastic drugs has been a major concern among practitioners and occupational health and safety managers.
    Objectives
    Considering the importance of safeguarding oncology personnel against antineoplastic drugs, the aim of this study was to validate a method for analysing cyclophosphamide (CPA) in urine samples as the biomarker of the exposure of oncology personnel of two hospitals in Tehran.
    Methods
    Standard urine samples were obtained from a healthy man without having any exposure to CPA drug. The standards urine samples of CPA within the concentration range of 0.02 to 50 microgram per liter (µg/L) were prepared by diluting the urine stock solution. Ifosfamide (IFO) was added as an internal standard at a concentration of 20 µg/L. CPA and IFO analysis by gas chromatography-electron capture detector (GC-ECD) in this study was confirmed by gas chromatography-mass spectrometry (GC-MS) for verification of their peak retention times and MS signature at 95% confidence.
    Results
    Urinary CPA concentrations as the biomarker of the exposure of the oncology personnel were detected within the range of 0.52 to 21.4 µg/L. The drug presence in the urine of 31% (10 of 32) of two hospital staff indicate the biological monitoring potential to recognition of worker’s exposure.
    Conclusions
    In general, biological monitoring of oncology personnel could be a useful tool for assessing occupational exposure through all routes and efficacy of the current safety measures. Owing to higher values of urinary CPA in this study compared to the studies of their colleagues abroad stringent control measures were deemed necessary.
    Keywords: Biological Monitoring, Cyclophosphamide, Occupational Exposure, Oncology Personnel
  • Babak Javanmard , Mohammad Reza Yousefi , Mahsa Ahadi , Morteza Fallah Karkan * Page 6
    Introduction
    Primitive neuroectodermal tumor (PNET) is a very rare type of prostate sarcoma that mostly occurs in young adults, and it is associated with a poor prognosis.
    Case Presentation
    A 37-year-old male was admitted with intermittent painless gross hematuria from 1 month prior to admission. Cystosocopy, abdominopelvic computed tomography scan (ACTS), and magnetic resonance imaging (MRI) revealed huge prostate. All tumor markers were negative and pathology findings of trans-rectal ultrasonographic biopsy (TRUS Bx) and trans-urethral resection of prostate (TURP) were consistent with severely inflamed prostatic urethra with no evidence of malignancy. The patient underwent radical prostatectomy. Histopathology of the specimens showed malignant neoplasm of small round and oval cells suggestive of PNET. Immunohistochemistry (IHC) study results on CD99 were positive.
    Conclusions
    We report a rare uncommon case of prostate PNET presented by intermittent painless gross hematuria. As the prognosis is very poor, medical staff should pay enough attention to the differential diagnosis, choosing the best treatment and subjects close follow-up.
    Keywords: Primitive Neuroectodermal Tumor, Extra-Skeletal Ewing’s Sarcoma, Prostate Sarcoma, CD99
  • Fatemeh Nili , Vahid Soleimani , Niusha Nobari , Hana Saffar , Arghavan Etebarian * Page 7
    Introduction
    Anaplastic lymphoma kinase-positive (ALK+) anaplastic large cell lymphoma is a rare subtype of non-Hodgkin lymphomas, which is usually presented as a systemic advanced stage disease. Extranodal involvement is common in skin, bone, soft tissue, lung and liver. Primary presentation in oral cavity is extremely rare.
    Case Presentation
    Here, a 28-year-old man with gingival swelling in the left mandibular molar area after tooth extraction and regional lymphadenopathy is reported. Microscopic examination revealed anaplastic large lymphoid cells with the positive expression of ALK protein.
    Conclusions
    Although the overall survival of ALK-positive anaplastic large cell lymphoma is better than other types of T-cell lymphomas, it is not clear for its oral counterparts.
    Keywords: Anaplastic Lymphoma Kinase-Positive, Anaplastic Large Cell Lymphoma, Oral Cavity